Seizure freedom · people with epilepsy
It is very uncertain whether rapid changes seizure freedom after 1 year of AED withdrawal compared with slow withdrawal of antiepileptic drugs (very low certainty).
3 findings from 1 review
RR 0.76 [0.58, 1.01]
1 study · 149 participants
Very low
RR 0.87 [0.58, 1.29]
1 study · 149 participants
Very low
RR 1.4 [0.54, 3.65]
1 study · 149 participants
Very low
Completion of withdrawal treatment − Outpatient · Adults or adolescents with opioid dependence
It is very uncertain whether rapid changes completion of withdrawal treatment − Outpatient compared with slow taper of buprenorphine dose (very low certainty).
1 finding from 1 review
Abstinents at · Adults or adolescents with opioid dependence
Rapid showed no clear difference in number abstinent at completion of dose taper − Inpatient compared with slow taper of buprenorphine dose (low certainty).
1 finding from 1 review
Number abstinent at completion of dose taper − Outpatient · Adults or adolescents with opioid dependence
It is very uncertain whether rapid changes number abstinent at completion of dose taper − Outpatient compared with slow taper of buprenorphine dose (very low certainty).
1 finding from 1 review
Completion of withdrawal treatment − Inpatient · Adults or adolescents with opioid dependence
Rapid showed no clear difference in completion of withdrawal treatment − Inpatient compared with slow taper of buprenorphine dose (low certainty).
1 finding from 1 review
Complete response · patients with high‐risk neuroblastoma
Rapid COJEC showed no clear difference in complete response compared with standard induction therapies (low certainty).
1 finding from 1 review
Early toxicities (during preoperative chemotherapy): febrile neutropenia (2 or more episodes), proven fungal infections, septicemia (1 or more episodes), gastrointestinal toxicity (grade 3 or 4), renal toxicity (glomerular filtration rate < 80 ml/... · patients with high‐risk neuroblastoma
1 finding from 1 review
Treatment‐related mortality · patients with high‐risk neuroblastoma
Rapid COJEC showed no clear difference in treatment‐related mortality compared with standard induction therapies (low certainty).
1 finding from 1 review
Overall survival · patients with high‐risk neuroblastoma
Rapid COJEC showed no clear difference in overall survival compared with standard induction therapies (low certainty).
1 finding from 1 review
Progression‐free survival ‐ not reported · patients with high‐risk neuroblastoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Event‐free survival · patients with high‐risk neuroblastoma
Rapid COJEC showed no clear difference in event‐free survival compared with standard induction therapies (low certainty).
1 finding from 1 review
Late non‐hematological toxicities: any complication, renal toxicity (Glomerular Filtration Rate < 80 ml/min per body surface area of 1.73 m2), ototoxicity (Brock grade 1 to 4), endocrine complications (see table of included studies for included di... · patients with high‐risk neuroblastoma
1 finding from 1 review
Molar expansion · Children and adults with a posterior crossbite, without a Class III skeletal relationship, cleft lip or palate (or both), or other…
Semi-rapid maxillary expansion showed no clear difference in molar expansion compared with rapid maxillary expansion; GRADE not reported.
1 finding from 1 review
Canine expansion · Children and adults with a posterior crossbite, without a Class III skeletal relationship, cleft lip or palate (or both), or other…
Semi-rapid maxillary expansion showed no clear difference in canine expansion compared with rapid maxillary expansion; GRADE not reported.
1 finding from 1 review
ANB · Children and adolescents (aged 16 years or younger) with prominent lower front teeth (Class III malocclusion)
Facemask with rapid maxillary expansion (RME) showed no clear difference in ANB compared with facemask with alternating rapid maxillary expansion and constriction… (low certainty).
1 finding from 1 review
Overjet · Children and adolescents (aged 16 years or younger) with prominent lower front teeth (Class III malocclusion)
The review found no eligible studies for this question.
1 finding from 1 review
A-Nasion perpendicular (A-NPerp) · Children and adolescents (aged 16 years or younger) with prominent lower front teeth (Class III malocclusion)
Facemask with rapid maxillary expansion (RME) led to higher A-Nasion perpendicular (A-NPerp) compared with facemask with alternating rapid maxillary expansion and constriction…; GRADE not reported.
1 finding from 1 review
Wits appraisal · Children and adolescents (aged 16 years or younger) with prominent lower front teeth (Class III malocclusion)
Facemask with rapid maxillary expansion (RME) showed no clear difference in wits appraisal compared with facemask with alternating rapid maxillary expansion and constriction…; GRADE not reported.
1 finding from 1 review
ANB · Children and adolescents (aged 16 years or younger) with prominent lower front teeth (Class III malocclusion)
Facemask with rapid maxillary expansion (RME) led to lower ANB compared with reverse Twin Block with lip pads and rapid maxillary expander (RME); GRADE not reported.
1 finding from 1 review
Wits appraisal · Children and adolescents (aged 16 years or younger) with prominent lower front teeth (Class III malocclusion)
Facemask with rapid maxillary expansion (RME) led to lower wits appraisal compared with reverse Twin Block with lip pads and rapid maxillary expander (RME); GRADE not reported.
1 finding from 1 review